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Background: Familial renal hypouricemia (RHUC) is a hereditary disease characterized by hypouricemia, high renal
fractional excretion of uric acid (FE-UA) and can be complicated by acute kidney failure and nephrolithiasis.
Loss-of-function mutations in the SLC22A12 gene cause renal hypouricemia type 1 (RHUC1), whereas renal
hypouricemia type 2 (RHUC2) is caused by mutations in the SLC2A9 gene.
Case presentation: We describe a 24-year-old Pakistani man who was admitted twice to our hospital for severe
exercise-induced acute renal failure (EIARF), abdominal pain and fever; he had very low serum UA levels (0.2 mg/dl
the first time and 0.09 mg/dl the second time) and high FE-UA (200% and 732% respectively), suggestive of RHUC.
Mutational analyses of both urate transporters revealed a new compound heterozygosity for two distinct missense
mutations in the SLC2A9 gene: p.Arg380Trp, already identified in heterozygosity, and p.Gly216Arg, previously found
in homozygosity or compound heterozygosity in some RHUC2 patients. Compared with previously reported
patients harbouring these mutations, our proband showed the highest FE-UA levels, suggesting that the
combination of p.Arg380Trp and p.Gly216Arg mutations most severely affects the renal handling of UA.
Conclusions: The clinical and molecular findings from this patient and a review of the literature provide new
insights into the genotype-phenotype correlation of this disorder, supporting the evidence of an autosomal
recessive inheritance pattern for RHUC2. Further investigations into the functional properties of GLUT9, URAT1 and
other urate transporters are required to assess their potential research and clinical implications.
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Renal hypouricemia is a heterogeneous genetic disorder
characterized by impaired tubular transport, reabsorption
insufficiency and/or accelerated secretion of uric acid (UA)
accompanied by severe complications, such as exercise-
induced acute renal failure (EIARF), chronic kidney disease
(CKD) and nephrolithiasis. Diagnosis of renal hypouricemia
is based on biochemical markers, i.e., hypouricemia and in-
creased fractional excretion of UA (FE-UA).* Correspondence: colombi@med.unibs.it
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stated.Renal hypouricemia type 1 (RHUC1, MIM#220150)
is a recessive condition caused by mutations in the
SLC22A12 gene encoding the transporter URAT1, which
leads to a partial UA absorption defect [1-5]. Renal
hypouricemia type 2 (RHUC2, MIM#612076) is a disorder
caused by defects in the SLC2A9 gene encoding the fa-
cilitative glucose transporter 9 (GLUT9). Heterozygous
RHUC2 patients show UA values similar to those of
patients with URAT1 mutations, while homozygous
and/or compound heterozygous patients have consid-
erably lower serum UA levels (near 0 mg/dl) [normal
range 2.35–7.90 mg/dl] and higher renal UA excretion
(>100%) [normal range 4–14%] [6,7].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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gene have been described, whereas only a few patients
with defects in the SLC2A9 gene have been character-
ized. SLC22A12 and SLC2A9 are the two genes that
most commonly influence the serum level of UA,
exerting their effect by modifying renal UA absorption
[1,8]. The SLC22A12 gene encodes two transcript variants
of the URAT1 transporter, and both variants are specifically
expressed on the apical membrane of the proximal tubules
in the kidneys [1].
The human SLC2A9 gene encodes two isoforms of
GLUT9, long and short, through the use of alternative
promoters. GLUT9 is expressed in human kidney
proximal tubule epithelial cells, in particular, GLUT9L
might be localized to the basolateral side and GLUT9S to
the apical membrane, as suggested by expression studies
performed using the Madin-Darby canine kidney cells [9].
Dinour and coworkers speculated that UA efflux is medi-
ated solely by GLUT9L on the basolateral side, whereas UA
absorption from the tubular lumen is carried out not only
by URAT1, but also by GLUT9S and possibly other apical
transporters [10]. According to this hypothesis, in patients
with RHUC1, loss-of-function of URAT1 should produce
a partial UA absorption defect with a FE-UA of 40 to 90%,
whereas loss-of-function of GLUT9, in RHUC2 patients,
due to either homozygous or compound heterozygous
mutations, should preclude UA absorption by all the
apical transporters (including URAT1), through complete
blocking of UA efflux, resulting in a total UA reabsorption
defect with a FE-UA of >100% [10-12].
In patients with RHUC2, either heterozygous mutations
[11,12] or compound heterozygous and/or homozygous
mutations have been identified in SLC2A9 [6,7,10,13,14].
To date, in SLC2A9, a total of 12 mutations (9 missense/
nonsense, 1 small insertion, 1 gross insertion, and 1
gross deletion) are currently reported in the HGMD
professional 2012.4.
Heterozygous SLC2A9 mutations cause hypouricemia
mainly via haploinsufficiency [11,12,15]. In a number of
studies, homozygous and compound heterozygous loss-
of-function mutations have been found to cause severe
hypouricemia (serum UA near 0), markedly higher renal
excretion, and nephrolithiasis and EIARF in most patients
described from different ethnic groups [6,7,10,13,14]. Very
recently, it was demonstrated that homozygous and/or
compound heterozygous mutations do not necessarily lead
to severe hypouricemia and a FE-UA of >150% [7].
Here, we report a young Pakistani man with severe
EIARF who required temporary hemodialysis and who
presented with very low serum UA levels. The FE-UA
was high (>150%), confirming the clinical diagnosis of
RHUC. The severe clinical manifestation of low UA and
very high FE-UA were suggestive of RHUC2 secondary
to compound heterozygous or homozygous mutationsin SLC2A9. Mutational analysis of the SLC22A12 and
SLC2A9 genes revealed the presence of two previously
described mutations in the GLUT9 transporter, one
found only in heterozygosis and the other either in
compound heterozygosis or homozygosis, allowing RHUC2
diagnosis and providing new insights into the genotype-
phenotype correlation in this disorder.
Case presentation
A 24-year-old Pakistani man presented to the emergency
room of our hospital suffering from diffuse abdominal and
bilateral loin pain, diarrhea, vomiting and fever which
began three days after a cricket match. The laboratory
tests revealed kidney failure (serum creatinine 5.8 mg/dl;
reference range 0.5-1.2), and the patient was admitted
to our department. The patient appeared alert without
neurological deficits, his temperature was 38°C, blood
pressure was 146/75 mmHg, pulse was 72 beats per mi-
nute rhytmic and regular, respiratory rate was 16 breaths
per minute. Complete laboratory tests confirmed acute
renal failure (serum creatinine 6.3 mg/dl) with metabolic
acidosis, hypokalemia and hyperphosphatemia. Urinalysis
showed many UA crystals, microscopic hematuria and
significant eosinophiluria (2%) without proteinuria. The
patient’s serum UA was 2.9 mg/dl, creatine kinase was
1,155 U/l, and Prothrombin Time (PT) was 52% with an
International Normalized Ratio (INR) of 1.6. All other
laboratory tests were within the normal range (Table 1).
Renal ultrasound showed only mild cortical hyperecho-
genicity, and renal vasculature was normal. The patient
was not taking medications, and his medical history was
unremarkable except for recurrent episodes of loin pain
(frequently radiating to the right groin with fever and
vomiting) over the last five years. These episodes had
started frequently after cricket matches or other physical
activities. The family history was unremarkable except for a
28-year-old sister, who was noted to have similar episodes
of recurrent loin pain and vomiting.
Intravenous infusions of 5% dextrose, normal saline
and 1/6 M sodium bicarbonate were started. The next day,
kidney function worsened further, and one hemodialysis
session was performed.
A presumptive diagnosis of acute renal failure due to
tubulo-interstitial nephritis was made, and prednisone
therapy was started (67.5 mg/day, i.e., 1 mg/kg BW/day).
Kidney function gradually improved after the first
dialysis session, and over the following nine days, there
was complete recovery of renal function along with the
disappearance of loin and groin pain and fever. Laboratory
tests repeated before discharge were unremarkable, ex-
cept for a very low plasma UA level (0.2 mg/dl). Steroid
treatment was rapidly tapered off, and the patient was
discharged on the thirteenth day with a serum creatinine
level of 1.6 mg/dl.
Table 1 Patient’s laboratory tests at admission and discharge for both hospitalization episodes
Serum parameters Units Reference values 1st admission 1st discharge 2nd admission 2nd discharge
Hemoglobin g/dl 14-18 13.4 13.8 14.7 14.2
Platelets x103/mmc 130-400 204 236 244 254
White blood cells x103/mmc 4-10.8 8.220 12.250 9.900 7.920
Eosinophils % 0-8 3 0 2
Aspartate transaminase U/l 5-50 29 16 37 7
Alanine transaminase U/l 5-50 13 11 16 12
Lactate dehydrogenase U/l 125-220 191 208 233 115
Creatine kinase U/l 20-170 1155 203 723 25
Serum proteins g/dl 6-8 6.6 7
C reactive protein mg/l < 5 15.4 17.5
INR* 0.9-1.2 1.6 1.4 1.3 1.3
Partial thromboplastin time seconds 24-38 38 40 34 35
Serum creatinine mg/dl 0.5-1.2 12.0 1.6 2.1 0.9
Serum UA mg/dl 2.35–7.90 2.9 0.2 0.38 0.09
Urine UA mg/day 250-750 575 411
FE-UA % >150% >150%
-men 6-12 (200%) (732%)
-women 6-20
Serum sodium mmol/l 135-145 140 141 142 142
Serum potassium mmol/l 3.5-5 3.3 3.5 3.5 3.6
Serum calcium mg/dl 8.6-10.6 9.2 8.8 10.1 9.3
Serum phosphate mg/dl 2.7-4.5 6.2 3.6 2.2 3.6
Venous HCO3
– mmol/l 24-28 19 26 26 30
*INR: International Normalized Ratio.
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recurrent loin pain, vomiting, diarrhea and acute renal
failure (creatinine 2 mg/dl); two days before he had
played a cricket match and the day before he had taken
1 g of paracetamol to treat a fever above 38°C.
The physical examination only showed bilateral loin ten-
derness; there were no signs of fluid overload, blood pres-
sure was 121/68 mm Hg without orthostatic hypotension,
and body temperature was 37°C.
The chest radiogram was normal, and renal ultrasonog-
raphy showed normal-sized kidneys with only slightly in-
creased echogenicity. Blood tests (Table 1) showed serum
creatinine of 2.1 mg/dl, hypouricemia (0.4 mg/dl), hypo-
phosphatemia (2.2 mg/dl) and a slight increase in creatine
kinase (723 U/l). Urinalysis showed only rare red and white
blood cells and a mild mixed proteinuria (0.4 g/day). Blood
tests repeated after renal function recovery showed a very
low serum UA concentration (0.09 mg/dl). The daily urine
UA excretion was 411 mg with a FE-UA higher than
150%. This severe clinical manifestation, low UA and very
high FE-UA in both admissions were suggestive of RHUC,
which led us to perform mutational analyses of the
two known casual genes. The patient provided written,informed consent and authorized the processing of his
personal data according to Italian bioethics laws as
well as the collection of blood and urine samples for
biochemical and genetic analyses.
Genomic DNA was isolated from peripheral blood by
standard protocol and all the exons and intron flanking re-
gions of the SLC22A12 gene (NM_144585.2, NP_653186.2)
and of both SLC2A9 isoforms (GLUT9L, NM_020041.2,
NP_064425.2; GLUT9S, NM_001001290.1, NP_001001290.1)
were analyzed by direct sequencing with the ABI3130XL
Genetic Analyzer.
Sequence descriptions of the mutations were verified
using the Alamut software, version 2.2.
Sequencing analysis of SLC22A12 did not identify
casual mutations; however, in SLC2A9, two distinct
missense mutations were identified (Figure 1). In particu-
lar, heterozygosity for p.Gly216Arg and p.Arg380Trp
substitutions was identified. Both missense mutations
have already been described in patients with RHUC2:
the p.Gly216Arg mutation was found either in homo-
zygosis or in compound heterozygosity [7], and the
p.Arg380Trp substitution was found only in hetero-
zygosity [11].
Control
Patient
c.646G>A, p.Gly216Arg/GLUT9L
c.559G>A, p.Gly187Arg/GLUT9S
Control
Patient
c.1138C>T, p.Arg380Trp/GLUT9L
c.1051C>T, p.Arg351Trp/GLUT9S
Figure 1 Molecular characterization of the patient. Left panel: Sequence chromatogram showing the position of the heterozygous
c.646G>A transition (NM_020041.2, GLUT9L, exon 7) corresponding to c.559G>A (NM_00100290.1, GLUT9S, exon 7), leading to the p.Gly216Arg
missense mutation (NP_064425.2, GLUT9L) corresponding to p.Gly187Arg (NP_001001290.1, GLUT9S). Right panel: Sequence chromatogram with
the position of the heterozygous c.1138C>T transition (NM_020041.2, GLUT9L, exon 11) corresponding to c.1051C>T (NM_00100290.1, GLUT9S,
exon 11), leading to the p.Arg380Trp missense mutation (NP_064425.2, GLUT9L, corresponding to p.Arg351Trp (NP_001001290.1, GLUT9S).
Mutations are annotated according to HGVS nomenclature (www.hgvs.org/mutnomen). Nucleotide numbering is based on cDNA sequence
numbering, with +1 corresponding to the A of the ATG translation initiation codon 1 in the reference sequence. For protein numbering, +1
corresponds to the first translated amino acid.
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tions was not determined given the long distance between
the variants, and segregation analysis was not performed
owing to the unavailability of the proband’s family.
The p.Arg380Trp mutation occurs in the sugar transport
protein signatures 1/2, in the fourth cytoplasmic loop,
which is highly conserved in all known GLUT9 orthologs
[11]. Previous studies have shown that this arginine residue
plays a critical role in forming cytoplasmic anchor points
that are essential for the appropriate conformation of
GLUT proteins [16]. Loss of cytoplasmic anchor points of
the membrane topology results in a significant reduction
in UA transport activity in mutated GLUT9. In addition,
the p.Arg380Trp mutation was functionally characterized
in the Xenopus model, where it demonstrated a marked
reduction of UA transport activity compared to wild type
GLUT9 [11,15].
The p.Gly216Arg mutation occurs in the fifth trans-
membrane domain and replaces a highly conserved
glycine residue with a basic charged amino acid, whichstrongly suggests its pathogenicity, as also predicted by
the computational tools of the Alamut software.
Conclusions
We have described a 24-year-old Pakistani man with severe
RHUC2 and EIARF. This clinical report emphasizes the im-
portance of analyzing any unexpected data. Indeed, during
the patient’s first admission, his low serum UA levels,
as well as the presence of UA crystals in his urine, were
underestimated, and did not immediately address the
genetic testing for primary renal hypouricemia.
The differential diagnosis of EIARF usually includes
massive rhabdomyolysis or severe hypovolemia. More
rarely, some metabolic factor (hypo/hyperthyroidism, poorly
controlled diabetes, hypocortisolism, and hypokalemia)
can favor either hypovolemia or rhabdomyolysis. The envir-
onmental situation (altitude, humidity, and temperature),
exercise intensity, medications or toxins (snake venom,
insects, alcohol, stimulants, diet/herbal supplements,
anticholinergic agents, statins, etc.) and infections can
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should be considered (glycogen storage disorders, fatty acid
oxidation disorders, mitochondrial disorders, sickle-cell
anemia, and muscular dystrophy).
Our patient displayed neither significant rhabdomyolysis
nor identifiable causes. His serum UA concentration was
unexpectedly low during acute renal failure and decreased
to very low values when renal function recovered.
Hypouricemia is arbitrarily defined as a serum UA
concentration lower than 2 mg/dl (119 μmol/l). It is
due to either decreased production (isolated defect in
purine metabolism) or, more commonly, reduced renal
tubular reabsorption of UA. The latter can be inherited
(through mutation of genes encoding tubular reabsorption
transporters), acquired as a result of disease (severe liver
disease, malignancy, diabetes, acquired immunodeficiency
syndrome, and syndrome of inappropriate antidiuretic
hormone secretion) or as a result of drugs that enhance
UA excretion.
Differential diagnosis between the different causes of
hypouricemia is based on FE-UA. Hypouricemia with a high
FE-UA is found in the familiar form of renal hypouricemia,
diseases associated with Fanconi syndrome, hypervolemic
states and diseases that increase intracranial pressure
(cerebral salt-wasting syndrome) [17].
In our patient, a familial form of RHUC2 was considered
based on the lack of other causes of hyperuricosuric
hypouricemia, very low plasma UA, extremely elevated
FE-UA (>150%), clinical presentation, and history of a sister
with similar symptoms. EIARF associated with hyperurico-
suric familial hypouricemia occurs predominantly in young
males (male: female ratio of 8:1), mostly after strenuous
exercise, such as a short-distance race. The initial symp-
toms are nausea, vomiting, loin pain, abdominal pain,
general fatigue and low-grade fever.
Almost 25% of patients with RHUC2 experience recurrent
EIARF at various intervals. Serum UA level is normal or
only slightly reduced on presentation (due to renal failure)
and decreases to less than 1 mg/dl after renal recovery,
which usually occurs in all patients.
Our patient represents the most severe end of the
spectrum of RHUC2 clinical and biochemical characteristics.
In fact, SLC2A9 analysis identified two distinct missense
mutations (p.Gly216Arg and p.Arg380Trp); although segre-
gation analysis was not performed, the severe clinical pheno-
type strongly suggests that they are present in compound
heterozygosity. Both missense mutations have already been
described in patients with RHUC2, but they have never
been identified in combination in a single patient.
In previously documented patients, the recessive
p.Gly216Arg mutation was either homozygous or in com-
pound heterozygous patients [7], whereas the p.Arg380Trp
substitution was observed only in heterozygosity and
was therefore classified as a dominant mutation [11,15].Comparison of the clinical and biochemical characteristics
of our patient with the other recently reported patients pro-
vides new insights into the genotype-phenotype correlation
of SLC2A9 mutations associated with UA homeostasis. The
p.Arg380Trp substitution was one of the first causal muta-
tions identified in the SLC2A9 gene, being found in hetero-
zygosity in a Japanese mother and her son who had serum
UA levels of 1.5 and 2.7 mg/dl respectively, and an FE-UA
of ~15% [11]. These two patients were selected from the
large database of the personnel of the Japan Maritime
Self-Defense Force on the basis of UA levels, and severe
clinical manifestations were not recorded. Therefore, this
apparently dominant mutation alone is probably insufficient
to cause a complete clinical phenotype of the disease, i.e.,
EIARF and hospitalization (Table 2).
The p.Gly216Arg substitution was originally described
in a 14-year-old boy in compound heterozygosity with
the p.Asn333Ser mutation [7]. The patient presented with
EIARF (maximum serum creatinine level of 297 μmol/l)
following a cross-country run, and his serum UA concentra-
tion was consistently below the normal range at 0.67 mg/dl
(normal range 2.35–7.90 mg/dl), daily urinary UA excretion
was 2190 mg (normal range 250–750 mg), and FE-UA
was 93% (normal range 4–14%). The renal recovery was
complete, and after the original episode, he had further in-
cidences of mild abdominal pain and mild renal dysfunc-
tion following exercise. The p.Gly216Arg mutation was also
found in homozygosity in a 12-year-old patient presenting
with severe EIARF requiring dialysis, abdominal pain and
vomiting. His serum UA was found to be persistently low
at 0.5 mg/dl, his urinary UA excretion was 2050 mg/die,
and FE-UA was 45.8%; the patient recovered normal renal
function. Both of these patients presented with severe
EIARF, similar to our patient; however, their UA levels
were higher (0.67 and 0.5 mg/dl vs. 0.1 mg/dl) and the
FE-UA was significantly lower (93% and 45.8% vs. >150%)
compared with our patient. Therefore, we can speculate
that the p.Arg380Trp substitution most severely impairs
the GLUT9 function in comparison with the p.Gly216Arg
and p.Asn333Ser mutations, giving our compound hetero-
zygous patient an increased risk of EIARF.
To date, several studies have described the clinical and
molecular characteristics of different patients with a se-
vere type of RHUC2 caused by compound heterozygous
or homozygous loss-of-function mutations in the SLC2A9
gene, suggesting an autosomal recessive inheritance pattern
for RHUC2 (Table 2). In particular, Dinour et al. [10]
and Shima et al. [13] reported patients that were either
homozygous or compound heterozygous for mutations in
SLC2A9, who showed severe hypouricemia (0.1-0.7 mg/dl),
very high FE-UA (>150%) and a high incidence of EIARF,
nephrolithiasis and CKD compared with the asymptomatic
heterozygous carriers, who showed only moderately low
serum UA levels (Table 2).
Table 2 Molecular and clinical features of all RHUC2 patients reported to date
SLC2A9 mutations Status Gender Age Serum UA FE-UA Clinical
manifestations
References
(GLUT9L, NP_064425.2) (years) (mg/dl) (%)
p.Pro412Arg/WT Heterozygous Female 36 2.4 NA No [12]
p.Arg380Trp/WT Heterozygous Female 70 1.5 15.7% No [11]
Male 43 2.7 14.6% No
p.Arg198Cys/WT Heterozygous Female 32 2.1 NA No [11]
p.Leu75Arg/p.Leu75Arg Homozygous Male 67 0.67 >150% Nephrolithiasis, CKD [10]
Male 46 0.20 >150% EIARF
Male 36 0.04 >150% Nephrolithiasis
Female 10 0.01 >150% No
Male 24 0.2 >150% EIARF
Male 19 0.1 >150% EIARF
p.Leu75Arg/WT Heterozygous Female 64 4.5 5.4% No [10]
Female 28 2.0 21.7% No
Female 38 2.2 19.6% No
Female 48 3.4 7.5% No
Female 40 3.7 7.4% No
Female 44 3.1 12.4% No
Male 5 2.6 NA No
Female 15 2.4 NA No
Male 16 2.0 17% No
delExon7/delExon7 Homozygous Male 69 0.1 >150% Nephrolithiasis [10]
p.Gly236*/dupExon1a-11 Compound heterozygous Female 11 0.1 >150% EIARF [13]
p.Gly236*/WT Heterozygous Female 46 3.4 NA No [13]
dupExon1a-11/WT Heterozygous Male 52 4.8 NA No [13]
p.Ile119Hisfs*27/p.Ile119Hisfs*27 Homozygous Female 16 0.17 >150% No [6]
Male 21 0.17 >150% No
p.Ile119Hisfs*27/WT Heterozygous Male NA 5.6 7.6% No [6]
Female NA 2.9 12.8% No
p.Arg171Cys/p.Arg171Cys Homozygous Female 7.5 0.1 138% No [14]
Male 5.5 0.1 157% No
Female 2.3 0.2 88.8% No
p.Arg171Cys/WT Heterozygous Female 24 3.8 3.2% No [14]
Male 37 4.9 6.5% No
p.Thr125Met/p.Thr125Met Homozygous Male 84 0.2 >150% No [14]
p.Gly216Arg/p.Asn333Ser Compound heterozygous Male 14 0.67 93% EIARF [7]
p.Gly216Arg/p.Gly216Arg Homozygous Male 12 0.5 46% EIARF [7]
p.Gly216Arg/p.Arg380Trp Compound heterozygous Male 24 0.1 >150% EIARF This study
NA: not available; WT: wild type.
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mutations in SLC2A9 preclude UA absorption by all of
the apical transporters (including URAT1). Additional fac-
tors, such as sequence variation in other UA transporters
(SLC22A12, SLC17A3, ABCC4 and ABCG2), age, sex, diet,
drugs, physical activity, environment and volume status
can influence the degree of UA tubular absorption and therisk of EIARF or nephrolithiasis. These factors could ex-
plain the 7/17 (41%) reported asymptomatic patients with
homozygous/compound heterozygous SLC2A9 mutations
that show very low serum UA levels without clinical
complications (Table 2) [6,10,14].
The pathogenesis of EIARF is unclear. There are two
main hypotheses: one based on UA precipitation and the
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hypothesis proposes that if patients are exposed to a UA
load, they are likely to have exaggerated excretion of UA.
Prolonged or severe exercise is associated with an ele-
vation in UA production and urinary excretion. If this
condition is associated with hypovolemia, increased
urine concentration and low urine pH, it favors the
precipitation and crystallization of UA. The occurrence
of UA nephrolithiasis in patients with renal hypourice-
mia and the finding of renal tubular obstruction by UA
crystals in one patient with EIARF support a pathogen-
etic role for UA precipitation [18]. In our case this
pathogenetic mechanism is supported by the findings
of relative hypouricemia, urate crystals and red blood
cells in urine and loin pain during the most severe epi-
sode of EIARF.
The second pathogenetic hypothesis is based on the
powerful antioxidant activity of UA [6,7]. However, this
hypothesis is in discrepancy with the evidence that ARF
does not usually occur in patients with low hypouricemia
due to classical xanthinuria, either type I, deficient in
xanthine dehydrogenase (XDH) activity (MIM#278300);
or type II, deficient in both XDH and aldehyde oxidase
(MIM#603592) [19]. This suggests that hypouricemia alone,
probably, could not contribute to ARF in patients with
primary renal hypouricemia.
One could speculate why our patient had only two
episodes of EIARF at the age of 24 and not all the times
he had anaerobic physical activity. Possibly not all the
exercises cause renal failure; other factors like duration and
strength of the exercise, environmental temperature, rela-
tive humidity, state of normal or reduced hydration of the
subject, changes in urine pH due to different foods and use
of some drugs could play a role. Due to the severity of renal
hypouricemia, our patient was instructed to restrict strenu-
ous anaerobic exercise and take sufficient water after
exercise. To prevent recurrence of EIARF prophylaxis
with allopurinol, oral supplementation of antioxidants
or scavengers, such as glutathione, vitamins C and E, and
beta-carotene, are also recommended [20].
In conclusion, the clinical and molecular findings on
the present patient provide new insights into this dis-
order, which is understood to a limited degree owing
to the small number of patients with SLC2A9 muta-
tions described to date. Further investigations of the
functional properties of GLUT9, URAT1 and other urate
transporters are required to assess their potential research
and clinical implications.
Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompanying
images. A copy of the written consent is available for review
by the Editor of this journal.Abbreviations
CKD: Chronic kidney disease; EIARF: Exercise-induced acute renal failure;
FE-UA: Fractional excretion of uric acid; RHUC: Renal hypouricaemia;
UA: Uric acid.
Competing interests
The authors declared they have no competing of interests.
Authors’ contributions
GJ, NC, MR, MC and GC designed the study. GJ, MG, PM, FV, SP and GC
made the clinical diagnosis of the patient and performed the follow-up. MR,
NC and SQ performed the molecular analyses. MR, NC, GJ, MC and GC
researched the literature, reviewed and prepared the manuscript. MC and GC
edited and coordinated the manuscript. All of the authors discussed, read,
and approved the final manuscript.
Acknowledgments
Work funded by Ministero dell’Istruzione dell’Università e della Ricerca,
Fondo per gli Investimenti della Ricerca di Base 2011–2012.
Author details
1Operative Unit of Nephrology, Department of Medical and Surgical
Specialties, Radiological Sciences and Public Health, University Hospital
Spedali Civili, Brescia, Italy. 2Division of Biology and Genetics, Department of
Molecular and Translational Medicine, University of Brescia, Viale Europa 11,
25123 Brescia, Italy.
Received: 3 September 2013 Accepted: 26 December 2013
Published: 7 January 2014
References
1. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH,
Hosoyamada M, Takeda M, Sekine T, Igarashi T, Matsuo H, Kikuchi Y, Oda T,
Ichida K, Hosoya T, Shimokata K, Niwa T, Kanai Y, Endou H: Molecular
identification of a renal urate anion exchanger that regulates blood
urate levels. Nature 2002, 417(6887):447–452.
2. Ichida K, Hosoyamada M, Hisatome I, Enomoto A, Hikita M, Endou H,
Hosoya T: Clinical and molecular analysis of patients with renal
hypouricemia in Japan-influence of URAT1 gene on urinary urate
excretion. J Am Soc Nephrol 2004, 15(1):164–173.
3. Ishikawa I, Nakagawa M, Hayama S, Yoshida S, Date T: Acute renal failure
with severe loin pain and patchy renal ischaemia after anaerobic
exercise (ALPE) (exercise-induced acute renal failure) in a father and
child with URAT1 mutations beyond the W258X mutation.
Nephrol Dial Transplant 2005, 20(5):1015.
4. Takahashi T, Tsuchida S, Oyamada T, Ohno T, Miyashita M, Saito S, Komatsu
K, Takashina K, Takada G: Recurrent URAT1 gene mutations and
prevalence of renal hypouricemia in Japanese. Pediatr Nephrol 2005,
20(5):576–578.
5. Stiburkova B, Sebesta I, Ichida K, Nakamura M, Hulkova H, Krylov V,
Kryspinova L, Jahnova H: Novel allelic variants and evidence for a prevalent
mutation in URAT1 causing renal hypouricemia: biochemical, genetics and
functional analysis. Eur J Hum Genet 2013. doi: 10.1038/ejhg.2013.3.
6. Stiburkova B, Ichida K, Sebesta I: Novel homozygous insertion in SLC2A9
gene caused renal hypouricemia. Mol Genet Metab 2011, 102(4):430–435.
7. Stiburkova B, Taylor J, Marinaki AM, Sebesta I: Acute kidney injury in two
children caused by renal hypouricaemia type 2. Pediatr Nephrol 2012,
27(8):1411–1415.
8. Doring A, Gieger C, Mehta D, Gohlke H, Prokisch H, Coassin S, Fischer G,
Henke K, Klopp N, Kronenberg F, Paulweber B, Pfeufer A, Rosskopf D, Volzke
H, Illig T, Meitinger T, Wichmann HE, Meisinger C: SLC2A9 influences uric
acid concentrations with pronounced sex-specific effects. Nat Genet 2008,
40(4):430–436.
9. Augustin R, Carayannopoulos MO, Dowd LO, Phay JE, Moley JF, Moley KH:
Identification and characterization of human glucose transporter-like
protein-9 (GLUT9): alternative splicing alters trafficking. J Biol Chem 2004,
279(16):16229–16236.
10. Dinour D, Gray NK, Campbell S, Shu X, Sawyer L, Richardson W, Rechavi G,
Amariglio N, Ganon L, Sela BA, Bahat H, Goldman M, Weissgarten J, Millar
MR, Wright AF, Holtzman EJ: Homozygous SLC2A9 mutations cause
severe renal hypouricemia. J Am Soc Nephrol 2010, 21(1):64–72.
Jeannin et al. BMC Medical Genetics 2014, 15:3 Page 8 of 8
http://www.biomedcentral.com/1471-2350/15/311. Matsuo H, Chiba T, Nagamori S, Nakayama A, Domoto H, Phetdee K,
Wiriyasermkul P, Kikuchi Y, Oda T, Nishiyama J, Nakamura T, Morimoto Y,
Kamakura K, Sakurai Y, Nonoyama S, Kanai Y, Shinomiya N: Mutations in
glucose transporter 9 gene SLC2A9 cause renal hypouricemia.
Am J Hum Genet 2008, 83(6):744–751.
12. Anzai N, Ichida K, Jutabha P, Kimura T, Babu E, Jin CJ, Srivastava S, Kitamura
K, Hisatome I, Endou H, Sakurai H: Plasma urate level is directly regulated
by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans.
J Biol Chem 2008, 283(46):32152.
13. Shima Y, Nozu K, Nozu Y, Togawa H, Kaito H, Matsuo M, Iijima K, Nakanishi
K, Yoshikawa N: Recurrent EIARF and PRES with severe renal
hypouricemia by compound heterozygous SLC2A9 mutation.
Pediatrics 2011, 127(6):e1621–e1625.
14. Dinour D, Gray NK, Ganon L, Knox AJ, Shalev H, Sela BA, Campbell S, Sawyer
L, Shu X, Valsamidou E, Landau D, Wright AF, Holtzman EJ: Two novel
homozygous SLC2A9 mutations cause renal hypouricemia type 2.
Nephrol Dial Transplant 2012, 27(3):1035–1041.
15. Kawamura Y, Matsuo H, Chiba T, Nagamori S, Nakayama A, Inoue H, Utsumi
Y, Oda T, Nishiyama J, Kanai Y, Shinomiya N: Pathogenic GLUT9 mutations
causing renal hypouricemia type 2 (RHUC2). Nucleosides Nucleotides
Nucleic Acids 2011, 30(12):1105–1111.
16. Sato M, Mueckler M: A conserved amino acid motif (R-X-G-R-R) in the
Glut1 glucose transporter is an important determinant of membrane
topology. J Biol Chem 1999, 274(35):24721–24725.
17. Devuyst O, Igarashi T: Renal Fanconi syndrome, Dent’s disease and
Bartter’s syndrome. In Genetics of Bone Biology and Skeletal Disease. Edited
by Thakker RV, Whyte MP, Eisman JA, Igarashi T. New York: Elsevier/Press;
2012:553–567.
18. Erley CM, Hirschberg RR, Hoefer W: Acute renal failure due to uric acid
nephropathy in a patient with renal hypouricemia. Klin Wochenschr 1989,
67(5):308–312.
19. Harkness RA, McCreanor GM, Simpson D, MacFadyen IR: Pregnancy in and
incidence of xanthine oxidase deficiency. J Inherit Metab Dis 1986,
9(4):407–408.
20. Nakamura A, Niimi R, Yanagawa Y: Renal hypouricemia in school-aged
children: screening of serum uric acid level before physical training.
Pediatr Nephrol 2006, 21(12):1898–1900.
doi:10.1186/1471-2350-15-3
Cite this article as: Jeannin et al.: Recurrent exercise-induced acute
renal failure in a young Pakistani man with severe renal
hypouricemia and SLC2A9 compound heterozygosity. BMC Medical
Genetics 2014 15:3.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
